Doxy PEP Toolkit for Healthcare Providers
A single dose of doxycycline post-exposure prophylaxis (Doxy PEP), provided within 24 to 72 hours of condomless oral, anal, or vaginal sex, has been proven to significantly reduce risk of getting syphilis, chlamydia and gonorrhea for cisgender men and transgender women (TGW) who report having multiple cisgender male or TGW sex partners.
While the epidemic of sexually transmitted infections (STIs) is slowing down, the number of STIs remains high in the U.S. Some populations are affected more severely, including African American and Hispanic populations, as well as gay and bisexual men.
Doxy PEP has been shown in several clinical trials to dramatically reduce incidence rates of gonorrhea, chlamydia, and syphilis in some key populations at high risk of STIs.
Doxy-PEP has been shown to reduce syphilis and chlamydia infections by more than 70%, and gonorrhea by 50%. Current efficacy data only applies to adult gay, bisexual, and other men who have sex with men (GBMSM), and TGWs. Studies among heterosexual cisgender women are ongoing.
This toolkit provides:
- Doxy PEP Clinic Guidance for Healthcare Providers – This document contains:
- Clinical protocol
- Guidelines for dosing, testing, reporting and counseling
- Communications resources, including:
- For patients:
- Cook County Health STI/HIV testing – FREE
- Every Mother Every Child maternal health website and print material
- Syphilis Stops with Me congenital syphilis information
- Testing sites in suburban Cook County
- For providers:
- Palm card
- For patients:
Updated July 11, 2025, 1:53 PM